Beijing, China, October 31, 2025 — From October 29 to 31, 2025, Gan & Lee Pharmaceuticals. (hereinafter referred to as Gan & Lee, stock code: 603087.SH) joined forces with its Brazilian partner BIOMM to participate in the XXV Congresso da Sociedade Brasileira de Diabetes 2025. Hosted by the Sociedade Brasileira de Diabetes, the congress gathered leading experts, healthcare professionals, and researchers from Brazil, Europe, and the United States, serving as an important international platform to showcase cutting-edge achievements and discuss emerging trends in diabetes prevention and management.

At this congress, Gan & Lee and BIOMM collaborated for the first time to create an immersive booth combining product displays with interactive experiences. The Gan & Lee team engaged deeply with attending healthcare professionals, exchanging insights on product features and clinical usage, and highlighting the significant advantages of insulin glargine in blood glucose management.

To enhance interactivity, both companies leveraged their operational expertise in insulin therapy to jointly develop the “GLARGILIN^® RUN” interactive game. Designed around an immersive experience, the game vividly demonstrated how different insulin therapies affect blood glucose fluctuations: characters using human insulin experienced larger swings, while those using GLARGILIN^® glargine insulin showed more stable and sustained glucose levels. This interactive game translated complex medical principles into an intuitive experience, clearly showcasing the benefits of insulin glargine while promoting healthy diet and scientific medication practices.

Through this event, Gan & Lee's "localized empowerment" strategy strongly supported BIOMM in deepening its presence in the Brazilian market, elevating the strategic collaboration to a new height. Building on its own strengths in products, technology, and market resources, Gan & Lee will continue to develop a global cooperation ecosystem, working with more partners to advance diabetes management worldwide and make high-quality treatment and healthy living accessible to a broader patient population.

About the XXV Congresso da Sociedade Brasileira de Diabetes 2025

The XXV Congresso da Sociedade Brasileira de Diabetes 2025 was held in Rio de Janeiro from October 29 to 31, 2025. The congress provided participants with a valuable platform to learn from and interact with leading experts from Brazil and around the world, share practical experiences and forge professional connections. The event featured expert interaction zones, thematic seminars, and academic debates, focusing on the latest research and developments in diabetes epidemiology, education, diagnosis, and treatment.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.